Patient With an Appointment for an Abdominal CT Scan and Able to Stand up for Height MeasurementTAILLENCT07864857
Automated and Reliable Estimation of Patient Height From CT Scan Using an Artificial Intelligence Algorithm
An observational study of Patient With an Appointment for an Abdominal CT Scan and Able to Stand up for Height Measurement, run by University Hospital, Grenoble at 1 site in France.
Trial summary
The TAILLE study is a single-center, non-interventional (RIPH3), uncontrolled, non-randomized, open-label study.prospective study conducted at CHU Grenoble Alpes. The goal is to evaluate the reliability of an AI algorithm developed as part of the TAILLE-pilot study to estimate height from abdominal CT scan data and… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Patient With an Appointment for an Abdominal CT Scan and Able to Stand up for Height Measurement
- How many people
- 200 participants
- Where
- 1 siteFrance
- Study dates
- 1 Nov 2026to 31 Dec 2027
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patient with a scheduled appointment for an abdominal CT scan in the Radiology Department of CHUGA
Who may be able to join
- Patient with a scheduled appointment for an abdominal CT scan in the Radiology Department of CHUGA
- Patient able to stand for height measurement
- Patient who does not object to participating in the study
- Patient affiliated with a social security
Who cannot join
- Patient with amputation of at least one limb
- Patient with metallic hardware in the spine (artifact)
- Protected person referred to in Articles L1121-5 to L1121-8 of the Code of Public Health
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Béatrice GENOUX contact
France1 site
University Hospital CHU Grenoble Alpes
Grenoble, 38043
Béatrice GENOUX, +33 7 77 72 91 32, bgenoux@chu-grenoble.fr
Cécile BETRY, Professor
About this study
Official title: Automated and Reliable Estimation of Patient Height From CT Scan Using an Artificial Intelligence Algorithm - Automated Height Estimation by Artificial Intelligence
The TAILLE study is a single-center, non-interventional (RIPH3), uncontrolled, non-randomized, open-label study.prospective study conducted at CHU Grenoble Alpes.
The goal is to evaluate the reliability of an AI algorithm developed as part of the TAILLE-pilot study to estimate height from abdominal CT scan data and relevant clinical data like age and gender.
Read more
The TAILLE-pilot study , is a pilot data study (RNIPH) aimed at developing artificial intelligence algorithms using a retrospective cohort, developed by our team. It is based on AI algorithms trained to predict height from abdominal CT scan volumes.
The TAILLE study therefore aims to prospectively evaluate the performance of this algorithm in a new cohort of adult patients scheduled for an abdominal CT scan. The TAILLE study hypothesize that height can be reliably estimated using this algorithm, potentially with greater accuracy at the individual level than self-reported height, the limitations of which have been documented in the literature.
As part of the TAILLE study, three methods will be compared of height estimation or measurement :
- CRA-measured height: height measured by a Clinical Research Associate (CRA), serving as the reference method;
- AI-estimated height: height estimated by the AI algorithm developed as part of the TAILLE-pilot study;
- Self-reported height: height reported by the patient.
Read the detailed description
The TAILLE study aims to prospectively validate the AI-algorithm, hypothesizing that it provides a more reliable estimate of height than self-reported height.
- Conditions
- Patient With an Appointment for an Abdominal CT Scan and Able to Stand up for Height Measurement
- Keywords
- AI algorithm, Height estimation, sarcopenia, malnutrition
- Medical subject headings
- Sarcopenia, Malnutrition
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Automated and Reliable Estimation of Patient Height From CT Scan | Height and weight measured and collection of patient self-reported height and weight |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assessment of the reliability of an AI algorithm developed as part of the TAILLE-pilot study to estimate height from abdominal CT scan and relevant clinical data, such as gender and sex
Assessment of the differences between CRA-measured height and AI-estimated height (CRA = Clinical Research Associate).
CRA-measured height is the reference
Measured: At enrollement
Secondary outcomes (5)
Assessment the most reliable method for height estimation by comparing self-reported and AI-estimated height with CRA-measured height
Differences between CRA-measured height and self-reported height, and between CRA-measured height and AI-estimated height
Measured: At enrollment
Identification of factors that may influence the reliability of the AI algorithm for height estimation, particularly gender and age
Difference between CRA-measured height and AI-estimated height according to factors that may affect the reliability of the algorithm, particularly gender and age
Measured: At enrollment
Assessment of the impact of using self-reported height and AI-estimated height on sarcopenia risk classification
In a hypothetical clinical context, change in sarcopenia risk category according to the SMI value calculated from the muscle area determined by the ODIASP software. Sarcopenia risk will be defined according to the thresholds established by the French National Authority for Health (HAS): men, SMI < 52.4 cm²/m²; women, SMI < 38.5 cm²/m²
Measured: At enrollment
Assessment of the impact of using self-reported height and AI-estimated height on the calculation of the theoretical chemotherapy dose
In a hypothetical clinical context, percentage of patients receiving a chemotherapy dose lower than 85% of the theoretical dose, a threshold below which impaired prognosis has been reported (Nielson et al., 2021). The dose will be calculated based on body surface area, which depends on the weight measured by the CRA and height. The analyses will focus in particular on commonly used chemotherapy regimens for gastrointestinal cancers: 5-fluorouracil 2,400 mg/m², gemcitabine 1,000 mg/m², and oxaliplatin 85 mg/m²
Measured: At enrollment
Assessment of the impact of using self-reported height and AI-estimated height on chronic kidney disease (CKD) staging estimated using the CKD-EPI equation adjusted for body surface area
In a hypothetical clinical context, change in CKD stage determined based on the estimated glomerular filtration rate calculated using the CKD-EPI equation adjusted for body surface area, using the same methodology as for CJS4. This endpoint will be analyzed provided that a serum creatinine value is available in the medical record
Measured: At enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Oct 2026
- Study start1 Nov 2026 (estimated)
- Primary completion30 Apr 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Patient With an Appointment for an Abdominal CT Scan and Able to Stand up for Height MeasurementStudies of the same condition, open and under way.
- More trials run by University Hospital, GrenobleThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- University Hospital, Grenoble
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Cécile BETRY, Professor, Principal investigator, Unuversity Hospital CHU Grenoble Alpes
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07864857
- Sponsor's protocol ID
- 38RC25.0196 TAILLE
- Acronym
- TAILLE
- Status last verified
- Oct 2026
- First submitted
- 2 Oct 2026
- Last updated
- 15 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 15 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Automated and Reliable Estimation of Patient Height From CT Scan Using an Artificial Intelligence Algorithm - Automated Height Estimation by Artificial Intelligence
- ClinicalTrials.gov ID
- NCT07864857
- Acronym / sponsor ID
- TAILLE / 38RC25.0196 TAILLE
- Conditions
- Patient With an Appointment for an Abdominal CT Scan and Able to Stand up for Height Measurement
- Keywords
- AI algorithm, Height estimation, sarcopenia, malnutrition
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- University Hospital, GrenobleUniversity, hospital or other
- Study start
- 1 Nov 2026 (estimated)
- Primary completion
- 30 Apr 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 8 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The TAILLE study is a single-center, non-interventional (RIPH3), uncontrolled, non-randomized, open-label study.prospective study conducted at CHU Grenoble Alpes.
The goal is to evaluate the reliability of an AI algorithm developed as part of the TAILLE-pilot study to estimate height from abdominal CT scan data and relevant clinical data like age and gender.
The TAILLE-pilot study , is a pilot data study (RNIPH) aimed at developing artificial intelligence algorithms using a retrospective cohort, developed by our team. It is based on AI algorithms trained to predict height from abdominal CT scan volumes.
The TAILLE study therefore aims to prospectively evaluate the performance of this algorithm in a new cohort of adult patients scheduled for an abdominal CT scan. The TAILLE study hypothesize that height can be reliably estimated using this algorithm, potentially with greater accuracy at the individual level than self-reported height, the limitations of which have been documented in the literature.
As part of the TAILLE study, three methods will be compared of height estimation or measurement :
- CRA-measured height: height measured by a Clinical Research Associate (CRA), serving as the reference method;
- AI-estimated height: height estimated by the AI algorithm developed as part of the TAILLE-pilot study;
- Self-reported height: height reported by the patient.
Detailed description
The TAILLE study aims to prospectively validate the AI-algorithm, hypothesizing that it provides a more reliable estimate of height than self-reported height.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Day
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Automated and Reliable Estimation of Patient Height From CT Scan | – | –Height and weight measured and collection of patient self-reported height and weight |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patient with a scheduled appointment for an abdominal CT scan in the Radiology Department of CHUGA
Key inclusion criteria (4 listed)
- Patient with a scheduled appointment for an abdominal CT scan in the Radiology Department of CHUGA
- Patient able to stand for height measurement
- Patient who does not object to participating in the study
- Patient affiliated with a social security
Key exclusion criteria (3 listed)
- Patient with amputation of at least one limb
- Patient with metallic hardware in the spine (artifact)
- Protected person referred to in Articles L1121-5 to L1121-8 of the Code of Public Health
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Assessment of the reliability of an AI algorithm developed as part of the TAILLE-pilot study to estimate height from abdominal CT scan and relevant clinical data, such as gender and sex
Time frame: At enrollement
Assessment of the differences between CRA-measured height and AI-estimated height (CRA = Clinical Research Associate). CRA-measured height is the reference
5 secondary outcomes
Assessment the most reliable method for height estimation by comparing self-reported and AI-estimated height with CRA-measured height
Time frame: At enrollment
Identification of factors that may influence the reliability of the AI algorithm for height estimation, particularly gender and age
Time frame: At enrollment
Assessment of the impact of using self-reported height and AI-estimated height on sarcopenia risk classification
Time frame: At enrollment
Assessment of the impact of using self-reported height and AI-estimated height on the calculation of the theoretical chemotherapy dose
Time frame: At enrollment
Assessment of the impact of using self-reported height and AI-estimated height on chronic kidney disease (CKD) staging estimated using the CKD-EPI equation adjusted for body surface area
Time frame: At enrollment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Oct 2026.
- Individual participant dataSharing planned: Undecided
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Béatrice GENOUX contact
Cécile BETRY, Professor principal investigator
Unuversity Hospital CHU Grenoble Alpes
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Patient With an Appointment for an Abdominal CT Scan and Able to Stand up for Height Measurement, run by University Hospital, Grenoble at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 15 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Cécile BETRY, Professor (4 76 76 55 09 ext. +33, cbetry@chu-grenoble.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assessment of the reliability of an AI algorithm developed as part of the TAILLE-pilot study to estimate height from abdominal CT scan and relevant clinical data, such as gender and sex (time frame: At enrollement). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2026.